新型抗结核药物研究进展  

Progress of New Antituberculosis Drugs

作　　者：刘洪涛[1] 李文燕[2] 任炳楠[1] LIU Hong-tao;LI Wen-yan;REN Bing-nan(Department of Pharmacy,Hebei General Hospital,Shijiazhuang 050051,China;College of Chemistry and Material Science,Hebei Normal University,Shijiazhuang 050024,China）.)

机构地区：[1]河北省人民医院药学部,河北石家庄050051 [2]河北师范大学化学与材料科学学院,河北石家庄050024

出　　处：《化学试剂》2018年第10期959-964,共6页Chemical Reagents

基　　金：河北省自然科学基金资助项目(H2018307055)

摘　　要：结核病导致全球每年180万患者死亡,是细菌性感染致死的主要因素。近年来随着HIV病毒引起的艾滋病协同感染的增加以及多药耐药菌的产生,迫切需要新型抗结核药物的出现。目前已有数个针对敏感和耐药结核分枝杆菌的化合物处于临床或临床前期研究,为耐药结核病的治疗带来希望。综述了目前正在使用和研发的抗结核药物的作用机制、体内外药理活性及临床研究数据,为抗结核药物的研究提供参考。Tuberculosis is a major disease causing every year 1.8 million deaths on worldwide and represents the leading cause of mortality resulting from a bacterial infection.Since the progression of HIV leading to co-infection with AIDS and the emergence of drug resistant strains,the need of new anti tuberculosis drugs was not overstated. Today,the pipeline of potential new treatments has been fulfilled with several compounds in clinical trials or preclinical development with promising activities against sensitive and resistant Mycobacterium tuberculosis strains.This review summarizes the action mechanism,pharmacological activity and clinical research data of anti-tuberculosis drugs currently in use or under development,which provided reference for the research of anti-tuberculosis drugs.

关 键 词：抗结核药物 作用机制 临床研究 

分 类 号：O626[理学—有机化学]